Stock Report

All about this stock under one free report Last Updated: 03-Oct-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

SMS Lifesciences Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: SMSLIFE | BSE: 540679

₹1,490.00

up-down-arrow ₹-11.40 (-0.76%)

As on 01-Oct-2026IST

Market cap

info icon

₹442 Cr

Revenue (TTM)

info icon

₹324 Cr

P/E Ratio

info icon

28

P/B Ratio

info icon

2.1

Div. Yield

info icon

0.1 %

Edit peer-selector-edit
SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 442 36,872 27,580 16,849 14,385
Revenue (₹ Cr)
 324 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 15.26 1,018.97 497.77 603.02 270.18
Net Margin (%)
 4.66 10.47 20.72 22.63 23.29
RoE (%)
 7.53 21.30 28.49 19.61 14.45
Price to Earnings
 27.99 36.46 55.41 27.94 52.24
Price-To-Book
 2.05 7.05 13.64 4.83 6.94

Income Statement (₹ Cr)

SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
324.23 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
327.32 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
283.33 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
40.90 1,943.92 762.90 836.69 388.38
Depreciation arrow
15.89 425.10 98.11 78.88 74.78
EBIT arrow
25.01 1,518.82 664.79 757.81 313.60
Interest arrow
6.48 148.45 26.33 5.43 0.26
Other Income arrow
3.09 47.39 30.80 73.83 51.50
Exceptional Items arrow
0.00 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
21.62 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
6.36 370.94 171.48 197.53 91.39
Profit after Tax arrow
15.26 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
213.55 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.54 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
68.58 723.57 345.47 142.73 50.51
Current Liabilities arrow
156.28 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
398.99 8,121.73 2,179.88 3,753.59 2,034.25

Assets (₹ Cr)

SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
277.03 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
163.11 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
398.99 8,121.73 2,179.88 3,753.59 2,034.25
Total Debt* arrow
84.01 731.70 136.01 0.00 0.38
Net Current Assets arrow
6.83 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
18.74 393.94 8.97 4.82 3.91

Cashflow (₹ Cr)

SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
34.05 851.71 317.40 391.52 244.52
Cash Flow from Investing Activities arrow
-15.00 -94.00 -298.16 -615.65 -159.99
Cash from Financing Activities arrow
-19.12 -813.96 24.96 -6.23 -98.77
Net Cash Inflow / Outflow arrow
-0.07 -56.25 44.21 -230.35 -14.24

Ratios

Profitability Ratios

 SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
12.60 22.49 23.45 25.50 29.62
ROE (%) arrow
7.53 21.30 28.49 19.61 14.45
ROA (%) arrow
3.61 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
7.71 15.68 28.03 29.25 28.29
Net Margin (%) arrow
4.66 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
-3.12 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
-1.19 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
-4.72 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
-8.47 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
11.17 50.94 18.89 20.94 18.74

Valuation Ratios

 SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
27.99 35.71 55.41 27.06 51.78
Price / Book Value arrow
2.05 7.05 13.64 4.83 6.94
Dividend Yield (%) arrow
0.10 0.19 0.16 0.36 0.55
EV/EBITDA arrow
12.83 19.51 35.94 19.20 35.97
Market Cap (₹ Cr) arrow
326.63 20,327.45 15,494.53 13,228.83 17,537.35

Solvency Ratios

 SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.23 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.26 0.11 -- -- 0.00
Current Ratio arrow
1.04 1.43 2.09 5.21 7.39
Quick Ratio arrow
0.53 0.82 1.37 3.85 5.46
Interest Coverage arrow
4.34 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 SMS Lifesciences Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
18.92 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.77 1.09 0.93 0.70 0.52
Receivable days arrow
56.81 87.83 85.17 132.12 132.49
Inventory Days arrow
70.27 78.64 90.97 102.08 68.07
Payable days arrow
133.15 174.97 137.94 133.54 123.94
Cash Conversion Cycle arrow
-6.07 -8.50 38.21 100.66 76.63
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...